Sanara MedTech discontinues Tissue Health Plus, reallocates resources to surgical business

Sanara MedTech Inc.

Completed evaluation of strategic alternatives for THP; ceased development in late September and will discontinue operations.
THP segment will be classified as discontinued operations; wind-down expected through end of 2025.
Total cash investment in THP expected $5.5M to $6.5M in H2 2025; no material cash expenses after year-end.
Management believes surgical business has greatest potential for sustainable long-term growth and value.
Further details to be discussed on Q3 2025 earnings call scheduled for November 12, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.